Loading stock data…
CYTK
$78.16+12.11 (+18.33%)
Market OpenUpdated 10:12 AM EDT
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cytokinetics, Incorporated in the Healthcare sector is trading at $78.16. The stock is currently near its 52-week high of $80.04, remaining 34.8% above its 200-day moving average. Technical signals show overbought RSI of 72 and bullish MACD crossover, explaining why CYTK maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 72) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$78.16
Potential Upside
5%
Whystock Fair Value$82.07
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus19 analysts
Buy
Mean target$93.32+19.4%
Range$67.00 – $136.00
Fundamentals
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.14B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.48
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
91.92%
Volume
Today's trading volume
7.94M
Recent News
Cytokinetics heart drug scores in closely watched trial
Myqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and opens up a multibillion-dollar market opportunity.
Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates?
ANI Pharmaceuticals, Novavax and three other biotechs show strong Earnings ESP signals, hinting at potential Q1 earnings beat as sector results roll in.
3 Biotech Stocks to Watch for Respectable Growth Beyond AI
Artificial intelligence has dominated investor attention for two years, but biotech revenue lines are also bending sharply higher. A small group of biotechs is building real commercial businesses around recently approved drugs, with growth profiles that stack up favorably against many AI darlings on a fundamentals basis. The three names below all reported Q4 2025 ... 3 Biotech Stocks to Watch for Respectable Growth Beyond AI
Moderna (MRNA) Reports Q1 Loss, Beats Revenue Estimates
Moderna (MRNA) delivered earnings and revenue surprises of +60.93% and +74.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Why The Cytokinetics (CYTK) Story Is Shifting After Myqorzo Approvals And ACACIA Expectations
The fair value estimate for Cytokinetics has shifted from US$79.56 to US$92.94, signaling a fresh look at what the shares might be worth in updated models. That change lines up with recent analyst reactions to Myqorzo approvals, the ACACIA non obstructive HCM trial setup, and revised loss and margin timelines that feed into a wide price target range from the high US$60s to just above US$100. As you read on, you will see how these moving pieces shape the evolving story around risk,...